The 2026 Social Security COLA came in at just 2.8%, which is barely keeping pace with a grocery bill, let alone replacing a paycheck. With the 10-year Treasury yielding 4.55% and the national average 12-month CD paying just 1.65%, retirees hunting real income are increasingly turning to a small group of blue-chip dividend payers with multi-decade track records of writing checks through every recession, rate cycle, and bear market. The five names below have paid and raised dividends long enough to earn the “sleep-at-night” label, and each one lands the income first, growth second. <\/p>\n
Realty Income (NYSE:O<\/a>) is the closest thing in equities to a payroll direct deposit. The REIT pays monthly at a current rate of $0.271 per share, with an annualized forward dividend of $3.252. Against the Alpha Vantage-reported dividend yield of 5.11%, that puts O comfortably above Treasuries as an income source. <\/p>\n Safety is the reason it earns a spot. Q1 2026 AFFO per share was $1.13, up 6.6% YoY, and management raised 2026 AFFO guidance to $4.41 to $4.44, which sits well above the annualized payout. Portfolio occupancy is 98.9% with 103.4% rent recapture, and net debt to annualized pro forma adjusted EBITDAre improved to 5.2x. The dividend track record speaks for itself: 670 consecutive monthly dividends and 114 consecutive quarterly increases, with 133 total increases since the 1994 NYSE listing. <\/p>\n Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Johnson & Johnson didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n The bull case for income investors: you get a monthly paycheck, an investment-grade net lease portfolio, and management guiding 2026 investments up to $9.5 billion from $8.0 billion. Shares are also on the move, up 19.69% year to date through July 16. <\/p>\n The caveat: rising rates hurt REIT math. Q1 2026 included $129.3 million in impairment provisions and a higher credit loss allowance, and European expansion adds FX exposure. <\/p>\n Johnson & Johnson (JNJ) <\/p>\n Johnson & Johnson (NYSE:JNJ<\/a>) is the archetype of a Dividend King. The board declared a quarterly dividend of $1.34, with an annualized forward dividend of $5.36, extending a run of 64 consecutive years of dividend increases. <\/p>\n Coverage is not a question here. Q1 2026 adjusted EPS came in at $2.70, and management guides FY 2026 adjusted EPS to $11.45 to $11.65 against that $5.36 annual dividend. FY 2025 free cash flow was $19.7 billion. Johnson & Johnson is one of only two U.S. companies historically holding a prime AAA credit rating, and Q1 2026 revenue hit $24.06 billion, up 9.9% year over year, with DARZALEX growing 22.5%, TREMFYA up 68.3%, and CARVYKTI up 62.1%. <\/p>\n The bull case: a diversified healthcare mega-cap with an oncology growth engine and a payout you can plan a retirement around. Shares are up 22.13% year to date, and 55.49% over the past year. <\/p>\n The caveat: STELARA biosimilar erosion is real, hitting the Innovative Medicine segment with a roughly 920 basis point drag, and litigation charges remain a recurring line item. <\/p>\n AbbVie (ABBV) <\/p>\n AbbVie (NYSE:ABBV<\/a>) pays a quarterly dividend of $1.73, with an annualized forward dividend of $6.92, and yields 2.76% per Alpha Vantage. AbbVie has raised its dividend every year since the 2013 spinoff from Abbott, and counting the Abbott heritage, the combined streak clears the Dividend Aristocrat threshold. <\/p>\n Coverage is generous. Q1 2026 adjusted diluted EPS was $2.65, and management raised FY 2026 adjusted EPS guidance to $14.08 to $14.28. The dividend growth curve is steep, moving from $0.57 per quarter in 2016 to $1.73 in 2026. The immunology franchise did the heavy lifting on Humira replacement, with Skyrizi at $4.48 billion (up 30.9%) and Rinvoq at $2.12 billion (up 23.3%) in Q1 2026, and neuroscience revenue up 26.0%. <\/p>\n The bull case: two blockbuster growth drivers have already replaced Humira faster than the Street expected, and the payout keeps compounding. Shares are up 160.34% over the past five years. <\/p>\n The caveat: Imbruvica sales fell 24.7%, Humira continues to slide, and a $744 million IPR&D charge weighed on Q1 EPS. <\/p>\n Verizon Communications (VZ) <\/p>\n Verizon Communications (NYSE:VZ<\/a>) is the ultra-high-yield anchor of this list, with a dividend yield of 6.46% and a quarterly dividend of $0.7075, annualized to $2.83 per share. Verizon has the longest dividend growth streak in U.S. telecom, at 19 consecutive years. <\/p>\n The safety story keeps improving. Q1 2026 adjusted EPS was $1.28, up 7.6% YoY, and management guides FY 2026 adjusted EPS to $4.95 to $4.99 and free cash flow above $21.5 billion, growing 7%+ versus $20.1 billion in FY 2025. That gives the $2.83 payout a wide FCF cushion. On the operations side, the Frontier acquisition closed January 20, 2026, pushing fiber broadband subscribers to roughly 10.8 million, up 41.9% YoY, and delivering the first positive Q1 postpaid phone net adds since 2013. <\/p>\n The bull case is straightforward income math: a yield above 6%, a growing FCF base, and volume growth returning under CEO Dan Schulman. Shares have added 13.15% year to date. <\/p>\n The caveat: the balance sheet carries $172.5 billion in total debt post-Frontier, and interest expense rose 18.9% year over year. <\/p>\n Altria Group (MO) <\/p>\n Altria Group (NYSE:MO<\/a>) has been a paycheck-replacement machine for decades. The current quarterly dividend is $1.06, annualized to $4.24, and Alpha Vantage lists the dividend yield at 5.96%, placing it firmly in high-yield territory. Altria has delivered its 60th dividend increase in the past 56 years, most recently a 3.9% raise in 2025. <\/p>\n The cash flow supports the check. Q1 2026 adjusted diluted EPS was $1.32, up 7.3% YoY, and management reaffirmed FY 2026 adjusted EPS guidance of $5.56 to $5.72. Altria paid $1.8 billion in dividends in Q1 2026 and $7.0 billion for full-year 2025, while also running a $2 billion buyback program that repurchased 4.5 million shares at an average $62.33 in Q1. The smokeable segment remains a fortress, with Q1 adjusted OCI up 6.3% to $2.68 billion at a 65.1% margin. <\/p>\n The bull case: pricing discipline offsets volume declines, buybacks compound the yield, and the stock is running hot, up 30.72% year to date. <\/p>\n The caveat: domestic cigarette industry volumes are down 5%, and Marlboro retail share slipped 1.4 points to 39.7%, with the on! pouch also losing category share. <\/p>\n The Paycheck Portfolio Takeaway <\/p>\n These five names cover the full income spectrum a retiree actually needs: monthly cash flow from Realty Income, healthcare-grade balance sheet quality from Johnson & Johnson, dividend growth acceleration from AbbVie, an ultra-high-yield anchor in Verizon, and a tobacco cash machine in Altria. Every one of them has raised the dividend through the last two recessions, and every one of them is currently generating cash flow that covers the payout with room to spare. For a retiree tired of watching a 2.8% COLA get eaten by insurance premiums, that combination is what a paycheck looks like. <\/p>\n Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks \u2014 and Johnson & Johnson didn’t make the cut. Grab the names FREE today<\/a>. <\/p>\n<\/a> 24\/7 Wall St Realty Income (O) <\/p>\n